As with other drugs, Ingrezza (valbenazine) can cause side effects, such as drowsiness and parkinsonism. If you are unable to tolerate Ingrezza’s side effects, talk with your doctor or ...

The FDA has approved Neurocrine Bioscience’s Ingrezza, the first ever licensed treatment for tardive dyskinesia or TD. The condition is characterised by uncontrollable movement of the body or ...

The company is best known for its drug, Ingrezza. Ingrezza treats tardive dyskinesia and chorea associated with Huntington's disease. Both are movement disorders. But in the fourth quarter ...

Biosciences announced top-line data from a Phase 4 study, KINECT-PRO, demonstrating clinically meaningful and sustained ...

Despite reporting a 26% growth in INGREZZA® (valbenazine) net product sales for the full year of 2024 compared to the previous year, the company's guidance for 2025 disappointed investors.